Together, this indicates that N-MYC cooperates with EZH2 to drive the neuroendocrine phenotype in prostate cancer, thereby providing a rationale for therapeutic strategies targeting EZH2 [103]. The gene discussed is MYCN; the disease is prostate cancer.